# Foralumab PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/foralumab

> The next catalyst for foralumab, sponsored by Tiziana Life Sciences Ltd (TLSA), is its topline data readout, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, year only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for foralumab?

The next catalyst for foralumab, sponsored by Tiziana Life Sciences Ltd (TLSA), is its topline data readout, Q1 2027. Press release filed with the SEC (EX-99): "Topline data are anticipated to be announced in Q1 2027." [Calendar and source filings](https://sec-api.dev/pdufa/foralumab)

Source: Press release filed with the SEC (EX-99), accession 0001213900-26-110008, https://www.sec.gov/Archives/edgar/data/1723069/000121390026110008/ea030884501ex99-1.htm (retrieved 2026-11-12). Last confirmed 2026-10-16. Cite: https://sec-api.dev/pdufa/foralumab#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | foralumab |
| Codes | TZLS-401, NI-0401 |
| Sponsor | Tiziana Life Sciences Ltd (TLSA) https://sec-api.dev/companies/tlsa/catalysts |
| Indications | non-active spms, [non-active secondary progressive multiple sclerosis](https://sec-api.dev/indications/non-active-secondary-progressive-multiple-sclerosis), [early alzheimer's disease](https://sec-api.dev/indications/early-alzheimer-s-disease), [Secondary Progressive Multiple Sclerosis](https://sec-api.dev/indications/secondary-progressive-multiple-sclerosis) |
| Modality | antibody |
| FDA designations | fast track, orphan |

## Timeline

### December 19, 2023: trial start

- Status: completed. Date confidence: exact. Stage: 2. Indication: non-active SPMS.
- First seen 2025-12-12, last confirmed 2026-01-22.
- SEC prospectus (424B) (accession 0001213900-26-006375): "December 19, 2023, we announced "first patient dosed" in our Phase 2a study comparing two doses of intranasal foralumab and placebo in patients with non-active SPMS." https://www.sec.gov/Archives/edgar/data/1723069/000121390026006375/ea0273606-424b5_tiziana.htm
- SEC prospectus (424B) (accession 0001213900-26-004895): "December 19, 2023, we announced "first patient dosed" in our Phase 2a study comparing two doses of intranasal foralumab and placebo in patients with non-active SPMS." https://www.sec.gov/Archives/edgar/data/1723069/000121390026004895/ea0273057-424b5_tizianalife.htm
- SEC prospectus (424B) (accession 0001213900-25-121308): "December 19, 2023, we announced "first patient dosed" in our Phase 2a study comparing two doses of intranasal foralumab and placebo in patients with non-active SPMS." https://www.sec.gov/Archives/edgar/data/1723069/000121390025121308/ea0269465-424b5_tizianalife.htm

### February 11, 2025: trial start

- Status: completed. Date confidence: exact.
- First seen 2025-02-11, last confirmed 2025-02-11.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-011952): "Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease" https://www.sec.gov/Archives/edgar/data/1723069/000121390025011952/ea023065001ex99-1_tiziana.htm

### April 23, 2025: trial start

- Status: completed. Date confidence: exact. Stage: 2. Indication: non-active secondary progressive multiple sclerosis.
- First seen 2025-04-23, last confirmed 2025-04-23.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-034332): "TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that dosing has commenced at the fourth clinical site in its ongoing Phase 2 trial evaluating intranasal foralumab in patients with non-active secondary progressive multiple sclerosis (na-SPMS)." https://www.sec.gov/Archives/edgar/data/1723069/000121390025034332/ea023921901ex99-1_tiziana.htm

### Q4 2025: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2025-05-06, last confirmed 2025-05-06.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-039892): "This trial is expected to reach top line data read out at the end of 2025." https://www.sec.gov/Archives/edgar/data/1723069/000121390025039892/ea024104101ex99-1_tiziana.htm
- SEC Form 10-K (accession 0001213900-25-040218): "Topline results are anticipated by Q4 2025." https://www.sec.gov/Archives/edgar/data/1723069/000121390025040218/ea0239559-20f_tiziana.htm

### December 17, 2025: trial start

- Status: completed. Date confidence: exact. Stage: 2. Indication: early Alzheimer's disease.
- First seen 2025-12-17, last confirmed 2025-12-17.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-122553): "Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that the first patient has been dosed with intranasal foralumab in its Phase 2 randomized, placebo-controlled clinical trial in patients with early Alzheimer's disease (AD)." https://www.sec.gov/Archives/edgar/data/1723069/000121390025122553/ea027004801ex99-1_tiziana.htm

### 2026: interim data readout

- Status: scheduled. Date confidence: year.
- First seen 2025-12-17, last confirmed 2025-12-17.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-122553): "Interim data are anticipated in 2026, with results intended to guide future development and potentially establish neuroimmune modulation as a key pillar in AD therapy." https://www.sec.gov/Archives/edgar/data/1723069/000121390025122553/ea027004801ex99-1_tiziana.htm

### 1H 2026: topline data readout

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2026-02-25, last confirmed 2026-02-25.
- Press release filed with the SEC (EX-99) (accession 0001213900-26-020114): "Tiziana is advancing intranasal foralumab in an ongoing randomized, double-blind, placebo-controlled Phase 2a trial (NCT06292923) in na-SPMS, with top-line data expected in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1723069/000121390026020114/ea027831601ex99-1.htm

### September 17, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Secondary Progressive Multiple Sclerosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06292923 (A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-09-17 (ACTUAL); Lead Sponsor Tiziana Life Sciences LTD." https://clinicaltrials.gov/study/NCT06292923

### Sep to Dec 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Secondary Progressive Multiple Sclerosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06292923 (A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-09-17 (ACTUAL); Lead Sponsor Tiziana Life Sciences LTD." https://clinicaltrials.gov/study/NCT06292923

### September 28, 2026: trial start

- Status: completed. Date confidence: exact.
- First seen 2026-09-28, last confirmed 2026-09-28.
- Press release filed with the SEC (EX-99) (accession 0001213900-26-103735): "Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab" https://www.sec.gov/Archives/edgar/data/1723069/000121390026103735/ea030682901ex99-1.htm

### November 2, 2026: topline data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2025-10-03, last confirmed 2026-11-02.
- Press release filed with the SEC (EX-99) (accession 0001213900-26-114650): "Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announced positive topline data in its Phase 2a INFORM-MS trial with intranasal foralumab (a human, anti-CD3 monoclonal antibody) in patients with non-active secondary progressive multiple sclerosis (na-SPMS)." https://www.sec.gov/Archives/edgar/data/1723069/000121390026114650/ea031046501ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-110270): "The top line data for the na-SPMS clinical trial are expected in Q4 2026, with Alzheimer's and MSA clinical trials results to follow soon after." https://www.sec.gov/Archives/edgar/data/1723069/000121390026110270/ea030885001ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-096118): "The top line data for all the clinical trials is expected in 2026 and the Directors are taking steps to put engagements and plans into place to secure sufficient capital to continue operations." https://www.sec.gov/Archives/edgar/data/1723069/000121390025096118/ea026019401ex99-1_tiziana.htm

### Q1 2027: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2026-10-16, last confirmed 2026-10-16.
- Press release filed with the SEC (EX-99) (accession 0001213900-26-110008): "Topline data are anticipated to be announced in Q1 2027." https://www.sec.gov/Archives/edgar/data/1723069/000121390026110008/ea030884501ex99-1.htm

## Same indication

- [Orelabrutinib](https://sec-api.dev/pdufa/orelabrutinib) (ZBIO)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/foralumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Foralumab PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/foralumab

```bibtex
@misc{secapidev_pdufa_foralumab_20261116,
  title        = {Foralumab PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/foralumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_foralumab_20261116","title":"Foralumab PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/foralumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
